DDR1 and colorectal carcinoma: In support of this hypothesis, it has been demonstrated that the DDR1 protein acts as an effective target for CRC therapy with targeted drugs such as the tyrosine kinase inhibitor nilotinb and monoclonal antibodies [29,30].